^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Tubulin inhibitor

    Related drugs:
    1d
    Single-cell dissection of persistent tumor antigens in non-responders reveals opportunities for TAA-targeted vaccination after neoadjuvant therapy in esophageal squamous cell carcinoma. (PubMed, J Immunother Cancer)
    Our study identifies key immune contributors correlated with response to neoadjuvant therapies and a panel of TAAs in non-responders. These findings support the development of TAA-targeted therapeutic vaccines and combination strategies incorporating ICB to overcome resistance in non-responders.
    Clinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • GZMB (Granzyme B)
    |
    cisplatin • AiRuiKa (camrelizumab) • albumin-bound paclitaxel
    1d
    Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P2, N=42, Completed, HonorHealth Research Institute | Active, not recruiting --> Completed
    Trial completion
    |
    cisplatin • gemcitabine • albumin-bound paclitaxel
    1d
    Nab-Paclitaxel Combined With Local Therapy in Relapsed SCLC (clinicaltrials.gov)
    P2, N=84, Not yet recruiting, Shanghai Pulmonary Hospital, Shanghai, China
    New P2 trial
    |
    albumin-bound paclitaxel
    2d
    A randomized, multicenter, phase III clinical study evaluating the efficacy of sequential paclitaxel and platinum based chemotherapy with synchronous tumor bed boost for cervical gastric-type adenocarcinoma with deep stromal invasion and above after radical hysterectomy (ChiCTR2600121751)
    P3, N=446, Recruiting, Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
    New P3 trial
    |
    paclitaxel
    2d
    Exploring the mechanism of TAM-induced paclitaxel resistance in breast cancer in the glutamine metabolic microenvironment using PTC microtumor models (ChiCTR2600118964)
    P=N/A, N=20, Zhejiang Provincial People's Hospital; Zhejiang Provincial People's Hospital
    New trial
    |
    paclitaxel
    2d
    Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer (clinicaltrials.gov)
    P2, N=36, Recruiting, Emory University | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    cisplatin • gemcitabine • albumin-bound paclitaxel
    2d
    Efficacy and Safety of Hyperbaric Oxygen Therapy in Improving Nab-paclitaxel-Induced Peripheral Neuropathy: A Randomized Clinical Trial (ChiCTR2600118386)
    P=N/A, N=160, Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences); Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sci
    New trial
    |
    albumin-bound paclitaxel
    2d
    Dabilimab in combination with paclitaxel (albumin-bound) and carboplatin neoadjuvant therapy for local advanced head and neck squamous cell carcinoma: a single-center, single-arm, open, Phase II clinica (ChiCTR2400091171)
    P2, N=24, Completed, The First Affiliated Hospital,Sun Yat-sen University; The First Affiliated Hospital,Sun Yat-sen University | Not yet recruiting --> Completed
    Trial completion
    |
    carboplatin • paclitaxel
    3d
    Multiomics Analysis Identifies Chromosomal Instability-Associated Immune-Related Signatures in Hepatocellular Carcinoma by Integrating Weighted Gene Coexpression Network Analysis (WGCNA) and Machine Learning. (PubMed, Hum Mutat)
    High-risk patients exhibited poorer survival, increased immune cell (particularly T cell) infiltration, higher sensitivity to chemotherapeutics like 5-fluorouracil and paclitaxel, and a higher TP53 mutation rate. Additionally, SSRP1 and SETDB1 were verified to promote the proliferation and invasion of HCC cells. This integrated model, combining genomic and immunological features, is a reliable prognostic tool for HCC patient stratification and personalized chemotherapy, promising for clinical translation and precision medicine in HCC.
    Journal
    |
    TP53 (Tumor protein P53) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • ARID2 (AT-Rich Interaction Domain 2) • SETDB1 (SET Domain Bifurcated Histone Lysine Methyltransferase 1) • SSRP1 (Structure Specific Recognition Protein 1)
    |
    TP53 mutation
    |
    paclitaxel • 5-fluorouracil
    3d
    Envafolimab combined with lenvatinib and albumin-bound paclitaxel in previously treated advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: a prospective, phase II, multi-cohort trial. (PubMed, Cancer Immunol Immunother)
    Second-line envafolimab-based combination therapy demonstrated promising effects in previously treated advanced GC, particularly in those who have not previously received ICIs.
    P2 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Lenvima (lenvatinib) • albumin-bound paclitaxel • Enweida (envafolimab)
    3d
    Capecitabine versus Paclitaxel After CDK4/6 Inhibitor Progression in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study. (PubMed, Breast Cancer (Dove Med Press))
    Capecitabine and paclitaxel demonstrated comparable efficacy after CDK4/6i progression, with no significant differences in PFS or OS. Given their distinct toxicity profiles, treatment selection should be individualized according to patient characteristics and tolerability.
    Journal • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    paclitaxel • capecitabine
    3d
    RTOG-1106: Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=138, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion
    |
    carboplatin • paclitaxel